-
Imported drug inspection reports are about to become electronic. What do pharmaceutical companies look forward to?
Time of Update: 2021-10-21
For example, Huankai Microorganism's dry powder culture medium, as long as you have the physical label, you can download the factory report on the official website .
-
Under the general trend of pharmaceutical reform, the personnel changes of pharmaceutical company executives will become more and more frequent
Time of Update: 2021-10-21
, Chief Financial Officer Ma Zhuo resigned due to job changes . Employee Supervisor of 3SBio Group resigns on October 11, 3SBio Group issued an announcement stating that on September 30, 2021
-
Corium Donepezil transdermal patch Adlarity new drug application is expected to be approved next year
Time of Update: 2021-10-21
release of donepezil, the Adlarity transdermal system can regularly deliver the drug through the skin. This design also avoids gastrointestinal absorption and related side effects . Corium
-
China Medical City has entered the stage of industrialization, and three more pharmaceutical companies have been approved for drug production licenses
Time of Update: 2021-10-21
The author has learned that recently, three more companies in China Medical City have successively obtained drug production licenses issued by the Jiangsu Provincial Drug Administration, and have officially entered the stage of industrialization .
-
For men: Merck's 9-valent HPV vaccine starts phase 3 clinical trials in China and plans to enroll 8,100 people
Time of Update: 2021-10-21
The batch issuance data of the China Inspection Institute shows that the number of nine-valent cervical cancer vaccines has increased significantly since its launch.
-
Children's drug concept stocks are booming, and many R&D and production companies report net profits increase by more than 30%
Time of Update: 2021-10-21
Poinsettia released a semi-annual performance report on the evening of July 29, stating that the operating income for the first half of 2021 was about 953 million yuan; the net profit attributable to shareholders of listed companies was about 1.
-
FDA grants AstraZeneca Tezepelumab orphan drug certification for the treatment of EoE
Time of Update: 2021-10-21
In addition, in the subgroup of patients with a baseline eosinophil count of <300 cells/μl, the trial also reached the primary endpoint: compared with placebo+SoC, tezepelumab+SoC treatment made AAER statistically significant and Decrease of clinical significance .
-
The third quarterly report intensive disclosure period!
Time of Update: 2021-10-21
Since October, listed companies have entered a period of intensive disclosure of third quarter reports . According to the data, as of October
-
The citizens of Wuhan ushered in hundreds of price-cut drugs, including 61 nationally selected varieties
Time of Update: 2021-10-21
the results of the proposed selection in Shanghai. This national procurement set a record high, with a large scale and a large variety of products, covering high blood pressure, Drugs for common and chronic diseases such as coronary heart disease
-
Has invested 350 million yuan in Hengrui's topical JAK1 inhibitor phase II clinical success
Time of Update: 2021-10-21
reached the effective endpoint indicators preset in the plan . >The results of the study showed that patients who received topical 0. 5%, 1. 0%, or 2. 0
-
Under policy changes, chain drugstore giants are expected to undertake sustained high performance
Time of Update: 2021-10-21
In recent years, with the advancement of policies such as prescription outflows, public hospital reforms, medical insurance control fees, volume purchases, and "dual channels", the pharmaceutical retail industry has undergone tremendous changes, and the industry concentration has continued to increase.
-
Beishangguang sells TOP10!
Time of Update: 2021-10-21
> According to data from Mi Nei. com, in 2021H1, the sales of terminal chemical drugs in Beijing public hospitals are close to 10 billion yuan, an increase of 27. 99% year-on-year, the most impressive increase among the three major cities
-
With local pharmaceutical companies investing heavily in innovation, R&D costs have soared
Time of Update: 2021-10-21
For example, as listed biomedical companies on the Sci-tech Innovation Board continued to increase R&D investment in the first half of the year, the total R&D investment amount has reached 5.
-
"Seeing the leopard in a tube", how is the boom in the three quarterly reports of the pharmaceutical equipment industry?
Time of Update: 2021-10-21
Many domestic pharmaceutical companies have accelerated their internationalization strategy this year, and overseas business is expected to usher in a new round of growth .
-
Digitization empowers the Chinese medicine industry and accelerates its entry into the "fast lane of development"
Time of Update: 2021-10-21
>With the deepening of digital marketing, big data analysis of market and customer needs has become more precise. Dong-e Ejiao uses this as a guide to continuously promote the transformation of classic Chinese medicine prescriptions and hospital
-
2021 Veeva China Business and Medical Summit is about to open
Time of Update: 2021-10-21
domestic and foreign pharmaceutical companies and ecological companies such as Sri Lanka Pharmaceuticals, Sansheng Pharmaceuticals, and Bojian visited the site to carry out high-value interactions such as theme discussions, case sharing, trend
-
Directors, deputy general managers...The wave of resignations of senior executives of listed pharmaceutical companies continues!
Time of Update: 2021-10-21
Kangyuan Pharmaceutical: Director resigns On October 11, Kangyuan Pharmaceutical announced that the company’s board of directors recently received a resignation report from Director, Deputy General Manager, Board Secretary and Chief Financial Officer Yin Honggang.
-
With the accelerated innovation of pharmaceutical companies, the AI drug research and development track is getting hotter and hotter
Time of Update: 2021-10-21
and development has continued to rise, in order to reduce investment pressure, pharmaceutical companies have begun to use AI platforms to conduct drug research and development cases . Recently, reports have
-
Guangdong ushered in 61 kinds of centralized procurement drugs, an average decrease of 55%
Time of Update: 2021-10-21
In addition to the aforementioned Guangdong Province’s price linkage for non-selected drugs of the same generic name, Henan Province also recently issued a notice on the evaluation results of the fifth batch of national centralized procurement of non-selected drugs.
-
Leading domestic pharmaceutical equipment industry, performance is expected to usher in a period of continuous growth
Time of Update: 2021-10-21
million yuan, a year-on-year increase of 101. 1%. . The industry predicts that in the context of the favorable pharmaceutical environment, the continuous optimization
